Perspective Therapeutics updates corporate presentation

Perspective Therapeutics, Inc. filed a current report to note that it updated its corporate presentation.

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. filed a current report to note that it updated its corporate presentation. The updated presentation, dated October 1, 2025, is furnished as Exhibit 99.1 to the report and incorporated by reference into the other events section.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Perspective Therapeutics (CATX) disclose in this 8-K filing?

Perspective Therapeutics disclosed that it updated its corporate presentation. The company filed the revised presentation as Exhibit 99.1 and incorporated it by reference into the other events section, providing investors with refreshed corporate and business information.

When did Perspective Therapeutics update its corporate presentation?

Perspective Therapeutics updated its corporate presentation on October 1, 2025. The same date appears on the current report, and the updated presentation is included as Exhibit 99.1 to provide the latest company materials to the market.

What is Exhibit 99.1 in the Perspective Therapeutics (CATX) 8-K?

Exhibit 99.1 is the updated corporate presentation of Perspective Therapeutics. The company filed this document with its current report and incorporated it by reference into the other events section to share refreshed corporate information with shareholders and other stakeholders.

Who signed the October 1, 2025 Perspective Therapeutics 8-K?

The October 1, 2025 current report for Perspective Therapeutics was signed by Joel Sendek. He signed in his capacity as Chief Financial Officer, indicating that he was duly authorized to sign the report on behalf of the company.

On which exchange does Perspective Therapeutics (CATX) list its common stock?

Perspective Therapeutics lists its common stock, with a par value of $0.001, on the NYSE American LLC. The trading symbol for the company’s common stock on this exchange is CATX, as identified in the current report.

What type of event is reported under Item 8.01 for Perspective Therapeutics?

Under Item 8.01, Perspective Therapeutics reports an “Other Event,” specifically the update of its corporate presentation. The company makes the updated presentation available as Exhibit 99.1 and incorporates it by reference into that item.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/01/2025 - 07:15 AM EDT Learn about SEC filing dates

false000072838700007283872025-10-012025-10-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 01, 2025

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-33407	41-1458152
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
c/o Perspective Therapeutics, Inc. 2401 Elliott Avenue Suite 320
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CATX		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 1, 2025, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PERSPECTIVE THERAPEUTICS, INC.
Date:	October 1, 2025	By:	/s/ Joel Sendek
			Joel Sendek Chief Financial Officer